Compare FMC Corp (FMC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs TransMedics Group Inc — how do they compare? FMC Corp trades at $10.14 (market cap $1.30B), while TransMedics Group Inc trades at $87.35 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 2.4× FMC Corp's market cap, and FMC Corp pays a 3.07% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| FMC | TMDX | |
|---|---|---|
Market Cap | $1.30B | $3.10B |
Sector | Basic Materials | Technology |
52-Week High | $40.69 | $150.42 |
52-Week Low | $10.01 | $61.99 |
Enterprise Value | $5.11B | $3.49B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $10.46, down 1.23% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $2.24 billion in 2025, with negative profitability margins, though recent quarters show mixed earnings beats. Analyst consensus is divided, with a $11.60 price target, while recent news highlights revenue challenges and strategic moves like a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and weak revenue trends, but debt reduction efforts and cost controls offer some stability. Key risks include competitive pressures and macroeconomic headwinds, while the current valuation metrics like P/S of 0.4 may attract value investors if operational improvements materialize.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
